Our website uses necessary cookies to enable basic functions and optional cookies to help us to enhance your user experience. Learn more about our cookie policy by clicking "Learn More".
Accept All Only Necessary Cookies
CSMS+ Diary icon

1.022 by AppCologne GmbH


May 2, 2019

About CSMS+ Diary

CSMS+ is used to document allergy complaints in the scope of clinical studies.

Thank you for participating in our study!

The Combined Symptom Medication Score (CSMS) is a parameter that was introduced throughout Europe to measure the impairment in allergy sufferers because of their allergy.

In the CSMS+ App, this parameter is combined with the validated Visual Analogue Scale for the rating of allergy symptoms. This enables the patient to individually determine his allergy symptoms on a day-to-day basis.

Therefore, it is essential that the allergy symptoms are documented on a daily basis. If you forget to document the symptoms, the App will remind you of the entry.

Please answer all questions of this little questionnaire and do not omit any answers.

The extent of the symptoms is rated with the Visual Analogue Scale. This is done by tipping on the vertical line on the scale and move it up and down to the position which represents best the symptoms.

Your physician will inform you on the results of this scientific analysis.

What's New in the Latest Version 1.022

Last updated on May 2, 2019

Bugfix

Translation Loading...

Additional APP Information

Latest Version

Request CSMS+ Diary Update 1.022

Uploaded by

Apaalibaba Alibaba

Requires Android

Android 4.2+

Available on

Get CSMS+ Diary on Google Play

Show More

CSMS+ Diary Screenshots

Comment Loading...
Languages
Subscribe to APKPure
Be the first to get access to the early release, news, and guides of the best Android games and apps.
No thanks
Sign Up
Subscribed Successfully!
You're now subscribed to APKPure.
Subscribe to APKPure
Be the first to get access to the early release, news, and guides of the best Android games and apps.
No thanks
Sign Up
Success!
You're now subscribed to our newsletter.